Taken together, a convergence of evidence now exists to suggest that activation of a serotonin 2B receptor is a potential target for Dravet syndrome therapy. The gene discussed is HTR2B; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.